Discounted Cash Flow (DCF) Analysis Unlevered

Cyclo Therapeutics, Inc. (CYTH)

$1.6

+0.11 (+7.38%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 1.6 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 1.241.011.010.901.591.771.982.212.462.75
Revenue (%)
EBITDA -3.82-4.24-7.53-8.93-14.27-11.91-13.30-14.84-16.57-18.50
EBITDA (%)
EBIT -3.83-4.26-7.53-8.94-14.29-11.93-13.31-14.86-16.59-18.52
EBIT (%)
Depreciation 0.010.010.010.010.020.020.020.020.020.03
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash 1.272.222.7812.8516.6110.8612.1213.5415.1116.87
Total Cash (%)
Account Receivables 0.090.120.180.110.540.300.330.370.410.46
Account Receivables (%)
Inventories 0.470.420.240.240.230.510.570.640.710.79
Inventories (%)
Accounts Payable 0.941.931.341.202.112.362.632.943.283.66
Accounts Payable (%)
Capital Expenditure -0.01-0-0-0.05-0.02-0.03-0.03-0.04-0.04-0.05
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 1.6
Beta -0.505
Diluted Shares Outstanding 6.37
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 1.146
Total Debt 0.17
Total Equity 10.19
Total Capital 10.36
Debt Weighting 1.65
Equity Weighting 98.35
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 1.241.011.010.901.591.771.982.212.462.75
EBITDA -3.82-4.24-7.53-8.93-14.27-11.91-13.30-14.84-16.57-18.50
EBIT -3.83-4.26-7.53-8.94-14.29-11.93-13.31-14.86-16.59-18.52
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT -3.83-4.26-7.53-8.94-14.29-11.93-13.31-14.86-16.59-18.52
Depreciation 0.010.010.010.010.020.020.020.020.020.03
Accounts Receivable --0.02-0.070.07-0.430.24-0.03-0.04-0.04-0.05
Inventories -0.050.1700.01-0.28-0.06-0.07-0.07-0.08
Accounts Payable -0.98-0.58-0.140.910.250.270.310.340.38
Capital Expenditure -0.01-0-0-0.05-0.02-0.03-0.03-0.04-0.04-0.05
UFCF -3.83-3.24-8-9.04-13.80-11.73-13.15-14.68-16.38-18.29
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -18.66
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -16.44
Equity Value -
Shares Outstanding 6.37
Equity Value Per Share -